Revolution Medicines' Zoldonrasib Shows Promising Results in Pancreatic Cancer Trials
Event summary
- Revolution Medicines presented Phase 1/2 clinical data for zoldonrasib combination regimens in RAS G12D metastatic pancreatic cancer at ESMO GI Congress 2026.
- Zoldonrasib plus chemotherapy showed an ORR of 82% with mFFX and 61% with GnP in first-line treatment.
- Zoldonrasib plus daraxonrasib demonstrated a 50% ORR in second-line and 47% ORR in third-line treatments.
- Company plans to initiate Phase 3 RASolute 309 trial evaluating zoldonrasib plus daraxonrasib versus GnP.
The big picture
Revolution Medicines' data suggests zoldonrasib could become a key player in treating RAS G12D pancreatic cancer, a subtype with poor prognosis. The company is positioning itself at the forefront of targeted oncology therapies, leveraging combination regimens to address unmet needs in this lethal malignancy.
What we're watching
- Clinical Validation
- Whether the Phase 3 RASolute 305 and 309 trials will confirm zoldonrasib's efficacy in first-line treatment.
- Regulatory Pathway
- The pace at which FDA may review daraxonrasib under its Breakthrough Therapy Designation.
- Competitive Positioning
- How Revolution Medicines differentiates itself in the RAS-targeted oncology space.
Related topics